<DOC>
	<DOCNO>NCT00835822</DOCNO>
	<brief_summary>The purpose study assess therapeutic efficacy safety Venocur Triplex® , administer BID 60 day patient Chronic Venous Insufficiency rat CEAP 2 4 , comparison Placebo group .</brief_summary>
	<brief_title>Efficacy Safety Use Venocur Triplex® Patients With Chronic Venous Insufficiency</brief_title>
	<detailed_description />
	<mesh_term>Venous Insufficiency</mesh_term>
	<criteria>The patient confirm his/her willingness participate study , inform aspect study might relevant his/her decision participate , sign date informed consent form , approve Institutional Review Board/ Ethics Committee ( IRB/EC ) Patients sex , age 18 year 65 year Presence uni bilateral varicose vein CVI , sex The patient 's CVI rat functional class CEAP 2 4 Present least one symptom CVI prior study leg pain , cramp , fatigue , heavy legs sensation . If female , patient circulatory disorder exclusively premenstrual period If patient pregnant breastfeed The patient receive anticoagulant less 15 day study start The patient use steroid antiinflammatory drug le 8 day study start The patient receive radio chemotherapy le 7 day study start The patient use diuretic , phlebotrophic venoactive drug past 8 day enrollment study The patient use compression stocking less 8 day study start Trauma surgical treatment past 30 day study start Prior surgical treatment relate CVI ( past 12 month surgery past 6 month sclerotherapy ) Immobilization low limb past 6 month Known allergy product 's ingredient Presence chronic inflammatory disease ( rheumatoid arthritis , instance ) , severe chronic infectious disease ( AIDS , tuberculosis , hanseniasis , etc . ) The patient suffer phlebitis deep venous thrombosis past 6 month study Fibrous lymphedema , primary secondary lymphedema lipoedema ; Concomitant erysipelas Active fungal infection low limbs Peripheral artery disease , cerebrovascular coronary disease Severe systemic condition ( heart failure , liver , pulmonary kidney failure , active neoplastic disease , severe arterial hypertension , uncontrolled diabetes , among others ) , past 6 month study start Hematocrit : &lt; 32.0 mL RBC/dL woman &lt; 36.0 mL RBC/dL men Hemoglobin : &lt; 11.0 mL g/dL woman &lt; 12.0 mL g/dL men ; Total protein fraction : Total protein &lt; 6.4 g/dL , Albumin &lt; 4.0 g/dL , Globulin &lt; 1g/dL Albumin/Globulin &lt; 0.9 % Serum creatinine : &gt; 1.0 mg/dL woman &gt; 1.2 mg/dL men patient dialysis Aminotranferases ( SGOT/AST and/or SGPT/ALT ) twice upper normal limit Participation study similar objective past 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Chronic Venous Insufficiency , Venocur Triplex®</keyword>
</DOC>